CSIMarket
 
Myriad Genetics Inc   (NASDAQ: MYGN)
Other Ticker:  
 
 
Price: $14.5100 $-0.83 -5.411%
Day's High: $15.37 Week Perf: -10.27 %
Day's Low: $ 14.50 30 Day Perf: -19.34 %
Volume (M): 965 52 Wk High: $ 29.30
Volume (M$): $ 14,002 52 Wk Avg: $22.77
Open: $15.32 52 Wk Low: $14.34



 Market Capitalization (Millions $) 1,319
 Shares Outstanding (Millions) 91
 Employees 2,700
 Revenues (TTM) (Millions $) 824
 Net Income (TTM) (Millions $) -116
 Cash Flow (TTM) (Millions $) 25
 Capital Exp. (TTM) (Millions $) 37

Myriad Genetics Inc
Myriad Genetics Inc.
is a leading biotechnology company in the United States that specifically focuses on the development and commercialization of molecular diagnostic tests.
The company is based in Salt Lake City, Utah and was founded in 1991.
Myriad Genetics is widely recognized for its innovative diagnostic tests, which help assess the risk of developing certain diseases, including inherited cancers, cardiovascular diseases, neurological disorders, and other genetic conditions.
The company has developed several proprietary technologies that enable its diagnostic tests to provide highly accurate and reliable results.
Myriad Genetics' most well-known product is its BRACAnalysis test, which is used to identify mutations in the BRCA1 and BRCA2 genes.
These mutations have been linked to breast and ovarian cancer, and the BRACAnalysis test is a key tool in helping healthcare professionals assess patients' risk of developing these diseases.
Myriad Genetics has also developed a range of other diagnostic tests, including its myRisk Hereditary Cancer test, which assesses the risk of developing several hereditary cancers using a multi-gene panel.
The company has also expanded into the field of companion diagnostics, working with pharmaceutical companies to develop tests that can identify patients who are likely to respond to specific treatments.
In addition to its diagnostic products, Myriad Genetics also operates a research and development division, which is dedicated to discovering new diagnostic and therapeutic technologies.
Myriad Genetics has received numerous awards and honors for its innovative work, including being named one of the world's most innovative companies by Forbes magazine.
As of 2021, Myriad Genetics has over 2,600 employees worldwide and its products are used in over 100 countries.
The company remains committed to advancing genetic testing and personalized medicine, with a focus on providing patients and healthcare professionals with the most accurate and reliable diagnostic information possible.


   Company Address: 322 North 2200 West Salt Lake City 84116 UT
   Company Phone Number: 584-3600   Stock Exchange / Ticker: NASDAQ MYGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CDIO        227.3% 
OCX   -1.53%    
VNRX        13.6% 
ALKS   -0.8%    
EXAS        0.88% 
FLGT        2.18% 
• View Complete Report
   



Partnership

In a significant stride towards enhancing access and equity in genetic testing, Myriad Genetics, Inc. (NASD...

Published Wed, Oct 16 2024 1:01 PM UTC

Advancing Genetic Testing: Myriad Genetics? Strategic Partnerships to Transform Precision Medicine In a significant stride towards enhancing access and equity in genetic testing, Myriad Genetics, Inc. (NASDAQ: MYGN), renowned for its leadership in genetic testing and precision medicine, has embarked on multiple collaborative initiatives designed to steer the future of person...

Partnership

Evolving Genetic Testing Myriad Genetics and Flatiron Health Team Up for Enhanced Patient Access

Published Tue, Oct 15 2024 1:00 PM UTC

In a groundbreaking move poised to reshape the landscape of healthcare, Myriad Genetics, a leader in genetic testing and innovative diagnostics, has announced a strategic partnership with Flatiron Health, a frontrunner in oncology data and software solutions. This collaboration aims to democratize access to genetic testing through seamless integration with electronic medical...

Partnership

?Unlocking the Future of Genomics Myriad Genetics Partners with Ultima Genomics to Uphold Oncology and Repro...

Published Thu, Oct 3 2024 1:00 PM UTC

In a pivotal move that could reshape the landscape of genetic testing, Myriad Genetics, a prominent player in precision medicine, has announced a strategic collaboration with Ultima Genomics, a company on the cutting edge of next-generation sequencing (NGS) technology. This partnership aims to leverage Ultima s UG 100 sequencing platform, which promises ultra-high throughput...

Licensing Agreement

Myriad Genetics Sells EndoPredict to Eurobio Scientific A Bold Step into Precision Medicine?s Future

Published Thu, Aug 1 2024 8:05 PM UTC

Myriad Genetics Reshapes Focus with Eurobio Scientific Deal: A Strategic Shift in Precision Medicine In a significant move aimed at bolstering its international presence and focusing on its core genetic testing operations, Myriad Genetics, Inc. (NASDAQ: MYGN) has completed the sale of its EndoPredict business to Eurobio Scientific, a prominent player in the in vitro medical ...

Product Service News

Myriad Genetics Validates RiskScore as a Groundbreaking Breast Cancer Risk Assessment Tool

Published Mon, Jun 3 2024 8:05 PM UTC

Myriad Genetics, Inc., a renowned leader in genetic testing and precision medicine, has recently unveiled a breakthrough study published in Genetics in Medicine. This study validates RiskScore, an innovative breast cancer risk assessment tool embedded within Myriad's MyRisk Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries w...







Myriad Genetics Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com